320 related articles for article (PubMed ID: 30303110)
1. CAR T-cell therapy: perceived need versus actual evidence.
The Lancet Oncology
Lancet Oncol; 2018 Oct; 19(10):1259. PubMed ID: 30303110
[No Abstract] [Full Text] [Related]
2. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
3. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.
Valand HA; Huda F; Tu RK
AJNR Am J Neuroradiol; 2019 May; 40(5):766-768. PubMed ID: 31048298
[TBL] [Abstract][Full Text] [Related]
5. Toxicities associated with immunotherapies for hematologic malignancies.
Leick MB; Maus MV
Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
[TBL] [Abstract][Full Text] [Related]
6. CAR T cells, immunologic and cellular therapies in hematologic malignancies.
Brentjens R; Davila ML
Best Pract Res Clin Haematol; 2018 Jun; 31(2):115-116. PubMed ID: 29909911
[No Abstract] [Full Text] [Related]
7. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.
Prasad V
Nat Rev Clin Oncol; 2018 Jan; 15(1):11-12. PubMed ID: 28975930
[No Abstract] [Full Text] [Related]
8. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
9. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cell therapy for haematological malignancies.
Selim AG; Tam CS
Med J Aust; 2020 Nov; 213(9):404-406.e1. PubMed ID: 32951222
[No Abstract] [Full Text] [Related]
11. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
12. CAR T Cell Therapy for Hematological Malignancies.
Yang X; Wang GX; Zhou JF
Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
[TBL] [Abstract][Full Text] [Related]
13. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
[TBL] [Abstract][Full Text] [Related]
14. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
15. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.
Murad JM; Graber DJ; Sentman CL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):176-183. PubMed ID: 29909918
[TBL] [Abstract][Full Text] [Related]
16. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
Zhou D; Zhu X; Xiao Y
Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.
Mochel JP; Ekker SC; Johannes CM; Jergens AE; Allenspach K; Bourgois-Mochel A; Knouse M; Benzekry S; Wierson W; LeBlanc AK; Kenderian SS
AAPS J; 2019 Apr; 21(3):50. PubMed ID: 30963322
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Rubio MT; Galaine J; Borg C; Daguindau É
Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
Zhang PF; Xie D; Li Q
Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
[TBL] [Abstract][Full Text] [Related]
20. CAR-T cell therapy and infection: a review.
Bupha-Intr O; Haeusler G; Chee L; Thursky K; Slavin M; Teh B
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):749-758. PubMed ID: 33249873
[No Abstract] [Full Text] [Related]
[Next] [New Search]